Although classic TKIs targeting BCR-ABL1 in CML cells makes patient’s condition acquired greatly improved, but is not curative and frequently limited by intolerance or resistance [37]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.